Definition

What Is Pancreatic Cancer?

Pancreatic cancer is among the most aggressive malignancies, with a current overall 5-year survival rate of ~13%¹. The dominant form (~85-90%) is pancreatic ductal adenocarcinoma (PDAC), arising from cells lining pancreatic ducts. Less common types include neuroendocrine tumors (PNETs) which have dramatically better prognosis.

The pancreas sits deep in the abdomen, allowing tumors to grow undetected. By the time symptoms emerge (jaundice, weight loss, abdominal pain), most cancers have already spread locally or distantly. Only ~20% are resectable at diagnosis, and resection is the only path to potential cure.

Risk factors include smoking, obesity, diabetes (both cause and consequence), chronic pancreatitis, family history (BRCA1/2, PALB2, ATM, Lynch syndrome, 5-10% are hereditary), and aging. New-onset diabetes after age 50 may be the earliest sign, pancreatic cancer can cause diabetes 1-3 years before diagnosis.

⚠️ Critical Warning Sign: New-onset diabetes after age 50 with unexplained weight loss should trigger pancreatic imaging. Sudden development of jaundice, "tea-colored urine," or steatorrhea (greasy stools) requires immediate evaluation. Early detection, even by weeks, meaningfully changes outcomes.

Stages by Resectability

🌱 Resectable (~15-20%)

Confined to pancreas without vascular involvement. Whipple procedure or distal pancreatectomy. 5-year survival ~30%. Adjuvant chemotherapy essential.

🌗 Borderline Resectable / Locally Advanced (~30%)

Major vessel involvement. Neoadjuvant chemo ± radiation, then attempt surgery. Aggressive multimodal approach. Increasingly more patients converted to resectable.

🌑 Metastatic (~50%)

Spread to liver, lungs, peritoneum. Systemic chemo (FOLFIRINOX or gemcitabine + nab-paclitaxel). Median survival improving but typically 1-2 years. Palliative care critical.

Signs & Symptoms

Symptoms of Pancreatic Cancer

Often vague and easily missed until advanced. Combination of symptoms in middle-aged or older adults warrants evaluation. New-onset diabetes is increasingly recognized as a critical early sign.

🔍 Key Warning Signs

🟡

Painless Jaundice

Yellow eyes/skin, dark urine, pale stools, itching. Tumor at pancreatic head obstructs common bile duct. Often THE presenting feature in resectable disease. URGENT evaluation.

⚖️

Unexplained Weight Loss

Significant unintentional weight loss (10+ pounds). Often accompanied by reduced appetite, early satiety, taste changes.

🩹

New-Onset Diabetes (After 50)

Increasingly recognized: new diabetes after 50, especially with weight loss, may precede pancreatic cancer diagnosis by 1-3 years. ENDPAC score helps identify high-risk patients for imaging.

😣

Upper Abdominal / Back Pain

Persistent dull ache in epigastric area radiating to back. Worse lying flat, better leaning forward. Often progressive. Indicates tumor invading retroperitoneal nerves.

⚠️ Additional Symptoms

💩

Steatorrhea (Fatty Stools)

Pale, greasy, foul-smelling, floating stools. Indicates pancreatic enzyme insufficiency from tumor blocking duct. Often accompanies weight loss.

🤢

Nausea, Vomiting, Early Satiety

Especially with tumor in head/body. May cause gastric outlet obstruction. Feeling full after small meals. Persistent nausea unexplained.

🦵

Blood Clots (DVT, PE)

Pancreatic cancer is highly thrombogenic, Trousseau's syndrome. Unexplained DVT or PE, especially "migrating" clots, may be presenting feature.

😔

Depression & Profound Fatigue

New-onset depression is sometimes a paraneoplastic phenomenon preceding pancreatic cancer diagnosis. Combined with weight loss, raises suspicion.

Diagnosis

How Pancreatic Cancer Is Diagnosed

🩻 Imaging & Biopsy

📡 Pancreas-Protocol CT

Multiphasic CT with pancreatic protocol. Identifies tumor, assesses vascular involvement (defines resectability), detects metastases. First-line imaging.

📡 MRI / MRCP

Better for cystic lesions, liver metastases. MRCP visualizes pancreatic and biliary ducts. Adjunct to CT.

🔬 EUS-Guided Biopsy

Endoscopic ultrasound with fine-needle aspiration. Most accurate biopsy method. Tissue for diagnosis + molecular testing.

🔬 ERCP (When Jaundiced)

For biliary stent placement to relieve obstructive jaundice + brush cytology. Therapeutic + diagnostic.

🧬 Molecular & Lab Workup

🩸 CA 19-9 (Tumor Marker)

Raised in many pancreatic cancers, but reported sensitivity varies widely and is lowest in early disease.⁶ Not a screening test (false positives common with biliary obstruction). Used for monitoring response and recurrence.

🧬 Germline Genetic Testing

NCCN recommends ALL pancreatic cancer patients get germline testing. BRCA1/2, PALB2, ATM, Lynch syndrome, implications for treatment (PARPi) and family screening.

🧬 Somatic Testing

KRAS (95%), TP53, CDKN2A, SMAD4.⁴ Identifies actionable mutations: BRCA1/2 (PARPi), microsatellite instability (immunotherapy), KRAS G12C (sotorasib trials).

📡 Staging Laparoscopy

For "resectable" disease, checks for peritoneal metastases not visible on imaging. Avoids futile laparotomy.

Treatment Comparison

Holistic vs. Conventional Treatment

🌿 HOLISTIC

💊 CONVENTIONAL

🌿

Holistic / Integrative Approach

CRITICAL nutritional support during conventional treatment. Cachexia is leading cause of death in pancreatic cancer.

Nutrition Priority

Aggressive nutritional support, sarcopenia/cachexia is leading cause of death

Pancreatic Enzymes

Pancreatic enzyme replacement therapy (PERT) essential, improves digestion, weight, treatment tolerance

Prevention

Smoking cessation, weight management, treat diabetes/chronic pancreatitis

Palliative Integration

Early palliative care improves quality of life and possibly survival⁹

Comprehensive Supportive Care

Pancreatic Enzyme Replacement Therapy (PERT): Creon, Zenpep, Pancreaze. CRITICAL with meals and snacks. Most pancreatic cancer patients are enzyme deficient. Dramatically improves weight, fatigue, and treatment tolerance.
Aggressive nutritional support: 1.2-1.5g/kg protein; adequate calories (35-40 kcal/kg); small frequent meals; oral nutrition supplement drinks
Address malabsorption: fat-soluble vitamin replacement (A, D, E, K), measure and replace
Diabetes management: most patients have or develop diabetes; coordinate with endocrinology
Smoking cessation, single most important prevention; improves treatment tolerance after diagnosis
Vitamin D optimization, pancreatic cancer patients commonly deficient; possibly affects prognosis
Omega-3 supplementation, may reduce cachexia, improve weight maintenance during chemo (Cochrane review)
Curcumin (bioavailable), anti-inflammatory; some evidence for adjunctive use; discuss with oncologist
Vitamin K2, pancreatic cancer is highly thrombogenic and DVT prophylaxis is often needed. Because of that, do not start or stop a K2 supplement without agreeing it with the clinician managing your anticoagulation
Address depression aggressively, common; improves quality of life and treatment adherence
Address pain, celiac plexus block can be life-changing for retroperitoneal pain
Early palliative care, Temel-style integration improves outcomes; not just end-of-life
Family genetic screening if hereditary mutation identified

✅ Pancreatic Enzymes Are Critical:² Almost every pancreatic cancer patient develops exocrine pancreatic insufficiency. PERT (Creon, Zenpep, Pancreaze) with every meal and snack dramatically improves digestion, weight maintenance, energy, and treatment tolerance. Most patients are under-dosed. Work with your oncology team to optimize.

💊

Conventional / Oncologic Approach

Surgery + chemotherapy stratified by stage. PARP inhibitors for BRCA carriers. Neoadjuvant approach increasingly used.

Resectable

Whipple or distal pancreatectomy + adjuvant FOLFIRINOX (modified) or gemcitabine + capecitabine

Borderline / Locally Advanced

Neoadjuvant FOLFIRINOX or gem/nab-paclitaxel ± radiation, then attempt resection

Metastatic

FOLFIRINOX (good performance status) or gemcitabine + nab-paclitaxel; sequential lines

BRCA1/2+

Olaparib (PARP inhibitor) maintenance after platinum response⁵; significant benefit

Modern Treatment Algorithms

Whipple Procedure (Pancreaticoduodenectomy): for tumors in pancreatic head. Major surgery, best done at high-volume centers (significantly better outcomes).
Distal pancreatectomy: for body/tail tumors. Often combined with splenectomy.
Adjuvant FOLFIRINOX (modified): standard of care if performance status allows (PRODIGE-24 trial). Significant improvement in disease-free survival.
Adjuvant gemcitabine + capecitabine: alternative if FOLFIRINOX not tolerated
Neoadjuvant chemotherapy: increasingly used; allows downstaging, identifies aggressive tumors before surgery, ensures all patients get systemic treatment
FOLFIRINOX (metastatic): 5-FU + leucovorin + irinotecan + oxaliplatin. Most active regimen but toxic. Reserved for good performance status patients.
Gemcitabine + nab-paclitaxel: alternative first-line for metastatic; better tolerated
Olaparib maintenance: for BRCA-mutated patients responding to platinum (POLO trial)
Pembrolizumab: for microsatellite instability-high (MSI-H) cases (~1-2%)
NALIRIFOX: new first-line option (NAPOLI 3 trial), liposomal irinotecan + 5-FU + oxaliplatin
Biliary stenting: for obstructive jaundice, endoscopic or percutaneous
Celiac plexus block: for retroperitoneal pain, significantly improves quality of life
Clinical trial enrollment: STRONGLY encouraged for all patients

⚠️ High-Volume Centers Matter³: Pancreatic surgery outcomes vary dramatically by surgeon and hospital volume. Whipple procedure mortality is <3% at high-volume centers but can be >10% at low-volume centers. Strongly consider referral to a specialized center.

Nutritional Strategy

Diet for Pancreatic Cancer

High calorie, high protein, with pancreatic enzymes at every meal. Cachexia prevention is paramount. Small frequent meals.

✅ Prioritize:

🥚 High Protein at Every Meal

Eggs, fish, poultry, dairy, legumes. 1.2-1.5g/kg/day minimum. Take pancreatic enzymes with every protein-containing meal.

🍳 Easily Digestible Foods

Eggs, fish, well-cooked vegetables, smoothies. Avoid very high-fiber foods if causing GI distress.

🥑 Healthy Fats (with PERT)

Olive oil, avocado, fatty fish. Need calorie-dense food + pancreatic enzymes to absorb. MCT oil bypasses pancreatic lipase needs.

🍽️ Small Frequent Meals

5-6 small meals/day vs 3 large. Better tolerance, improved absorption with enzymes, prevents nausea.

💧 Adequate Hydration

Diarrhea common (from disease and chemo). Track intake. Electrolyte solutions if losing significant volume.

❌ Avoid:

🚭 Smoking

Doubles pancreatic cancer risk. Continuing to smoke after diagnosis worsens treatment response. Quit at any time helps.

🥃 Alcohol

Heavy use causes chronic pancreatitis → cancer risk. During treatment, abstain, affects liver, drug metabolism, healing.

🍬 High-Fat Meals Without Enzymes

Cause diarrhea, steatorrhea, weight loss. Always take pancreatic enzymes (PERT) with fatty meals. MCT oil better tolerated.

🍔 Heavily Processed Foods

Pro-inflammatory, low nutrient density. Spend caloric intake on nutrient-dense foods that fight cachexia.

🍣 Raw Foods (During Chemo)

During chemo-induced neutropenia: avoid raw sushi, raw eggs, unpasteurized dairy, raw sprouts. Infection risk.

Supplement Protocol

Evidence-Based Supplements

CRITICAL: Pancreatic enzymes are the #1 supplement. Coordinate with oncology, many interactions with chemo.

Supplement	Mechanism & Evidence	Suggested Dose	Timing	Notes
Pancreatic Enzymes (PERT)	ESSENTIAL, most patients deficient. Improves digestion, absorption, weight, energy, treatment tolerance.	40,000-80,000 USP lipase per meal; 25,000 per snack	With every meal AND snack	Creon, Zenpep, Pancreaze, by prescription. Open capsule onto food if can't swallow. Doses often underestimated.
Fat-Soluble Vitamins (A, D, E, K)	Universal deficiency in pancreatic exocrine insufficiency. Test and replace.	Multivitamin + vitamin D at a dose set with your clinician + K2 200mcg	With fat meal + PERT	Test D level. Measure A and E levels if symptomatic. If you take warfarin, agree any vitamin K supplement with the clinician managing your anticoagulation before starting or stopping it: vitamin K antagonises warfarin, and changing your intake destabilises the INR. Consistency matters more than avoidance. This does not apply in the same way to direct oral anticoagulants such as apixaban or rivaroxaban.
Omega-3 (EPA/DHA)	Anti-cachexia effects (Cochrane review). May improve weight maintenance during chemo.	2,000-4,000mg EPA+DHA/day	With fat meal + PERT	Discuss with oncologist; some interactions with chemo.
Curcumin (Bioavailable)	Anti-inflammatory. Human evidence in pancreatic cancer is very thin: in a phase II trial of 25 patients on 8g/day, 2 showed biological activity and 1 had brief tumour regression. Poorly absorbed, and not established as beneficial.⁷	500-1,500mg/day (bioavailable form)	With fat meal	Discuss timing with oncologist.
Vitamin D3	Universal deficiency. Possibly affects prognosis. Anti-cancer effects in lab.	Test 25-OH-D first and set the dose with your clinician (target 40 to 60 ng/mL⁸, the Endocrine Society's preferred range)	With fat meal + PERT	Higher doses often needed due to malabsorption. Test 3 months.
MCT Oil (Medium-Chain Triglycerides)	Absorbs without pancreatic lipase, calorie source that bypasses enzyme deficiency.	1-3 tablespoons/day	Throughout day	Start low to avoid GI upset. Add to smoothies, coffee.
Whey Protein / Protein Powder	Easy way to boost protein intake when appetite limited. High-quality amino acid source.	20-40g protein/day from supplement	Between meals or with meals	Choose pancreatic-friendly forms, whey isolate or hydrolyzed if maldigesting.
Glutamine	Reduces chemo-induced mucositis, neuropathy. Supports gut barrier.	10-30g/day during chemo	Divided doses	Some controversy; discuss with oncologist.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed 27 August 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.¹⁰ Nothing on this page treats pancreatic cancer. The nutrition here is supportive care, and on this page that is not a small thing: sarcopenia and cachexia are a leading cause of death in pancreatic cancer, so maintaining weight and muscle genuinely affects how well treatment is tolerated. The single most useful item here is pancreatic enzyme replacement therapy, which is a prescription and is routinely under-dosed. None of it substitutes for surgery, chemotherapy or radiotherapy, and no dietary change should delay treatment. Tell your oncology team about every supplement. Two further things worth knowing: this cancer should be managed at a high-volume centre, and clinical trial enrolment is worth asking about at every stage.

SEER (National Cancer Institute) pancreatic cancer statistics. seer.cancer.gov. Source for the overall 5-year relative survival of roughly 13%, the share that is pancreatic ductal adenocarcinoma, and the stage distribution at diagnosis. The pooled survival figure is dominated by late presentation and is not an individual prognosis. ↩
On pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency affects the large majority of patients with pancreatic cancer, and PERT improves fat absorption, weight maintenance and treatment tolerance. Typical dosing is 40,000 to 80,000 USP lipase units with meals and about half that with snacks, taken through the meal rather than before it. Under-dosing is the usual error. Creon, Zenpep and Pancreaze are the prescription products available in the US; they are named because lipase content per capsule differs between them and the dose has to be matched to the product, not as an endorsement of a brand. ↩
On resectability and surgical outcomes: roughly 15 to 20% of patients are reported to present with resectable disease, and 5-year survival after resection with adjuvant chemotherapy is substantially better than for unresectable disease. Whipple mortality is consistently lower at high-volume centres, one of the better-replicated findings in surgical oncology; in the landmark national analysis, pancreatic resection showed the largest volume effect of any operation studied, 16.3% mortality at the lowest-volume hospitals against 3.8% at the highest, PubMed 11948273. This is a reason to ask where an operation will be done, not a reason to delay it. ↩
On molecular testing: KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas, PubMed 42635442, with TP53, CDKN2A and SMAD4 also common. Germline BRCA1/2 and PALB2 testing matters because it changes treatment, and microsatellite-instability-high tumours (roughly 1 to 2%) may respond to pembrolizumab. ↩
POLO trial: Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–327. Basis for PARP inhibitor maintenance after platinum-based chemotherapy in germline BRCA-mutated disease. ↩
On CA 19-9: reported sensitivity varies widely between studies and is lowest in early-stage disease, which is the reason it is not a screening test. Biliary obstruction and benign disease raise it, and a minority of people cannot express it at all because they lack the Lewis antigen. The figure of “around 80%” that circulates for this marker is unreliable: the studies that report it are often measuring specificity, or sensitivity in advanced disease, rather than the proportion of all pancreatic cancers that are marker-positive. It is used for monitoring response and recurrence. ↩
On curcumin in pancreatic cancer: Dhillon N, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499. PubMed 18628464. Twenty-five patients on 8 g/day: two showed clinical biological activity and one had a brief but marked tumour regression. Oral bioavailability was very poor. This is a signal worth studying, not a treatment. No randomized trial has shown benefit in pancreatic cancer. ↩
On vitamin D dosing: this page previously recommended an open-ended dose above the 4,000 IU/day adult tolerable upper intake level used across this site. It now says to test 25-OH-D first and set the dose with a clinician. Vitamin D deficiency is near-universal in pancreatic cancer and correcting it is reasonable; self-directed high-dose supplementation is not. ↩
On early palliative care: integrating palliative care alongside oncology treatment improves quality of life and mood, and in some trials survival, without shortening it. It is not end-of-life care and asking for it early is not giving up. ↩
National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic.